Thank you for submitting your manuscript for consideration by The EMBO Journal. Let me first of all apologise for the exceptionally long delay in getting back to you with a decision. Unfortunately, we experienced difficulties in finding suitable and willing referees for this manuscript and in addition two of the referees were not able to get back to us with their reports as quickly as initially expected. In fact, one of the referees has still not sent us his/her report. As the other two reports are in fair agreement I am taking a decision on your manuscript now to save you from further unnecessary loss of time.
Your manuscript has now been seen by two referees whose comments to the authors are shown below. As you will see none of the referees offers strong support for publication of the manuscript in The EMBO Journal. I will not repeat all their individual points of criticism here, but the both referees are not convinced that you were able to rule out convincingly possible alternative explanations one could come up with for the findings you present and all in all they thus feel that the conclusiveness and the completeness of the experiments is insufficient at this point to fully justify the conclusions drawn. Furthermore, it becomes clear that it cannot be predicted at this point whether the concerns raised and the controls required can be addressed adequately and whether the model you put forward can then be maintained. In such a situation, I am sorry to say that we cannot consider (and thus commit to) a revision and I therefore see little choice but to come to the conclusion that we cannot offer to publish the manuscript. even in a receptor where one VFT cannot bind ligand, the presence of two VFTs is necessary to activate 7TM domain(s). This makes it very likely that in GABA-B the movement of the two VFTs relative to each other serves to transmit the signal to 7TMs, as was proposed for mGluRs.
Presentation issues: 4. In the intro, the authors state "It is accepted that these 7 transmembrane domains (7TM) proteins can associate into dimers or oligomers (Ferre et al., 2009; Terrillon and Bouvier, 2004) , then possibly offering a new level of complexity and the development of more specific drugs", implying that this is a generally accepted paradigm. In fact, with the exception of class C receptors (to which GABA-B belongs), the issue of GPCR dimerization and its possible functional significance is highly controversial. The authors should clearly state that they are discussing class C receptors and avoid lumping all GPCRs together. 5. The text needs some editing. In the abstract, "receptor deleted of the GABAB2 extracellular domain" should read "receptor where the GABAB2 extracellular domain was deleted"; p.6, "largely diminished" should read "significantly diminished"; in many places "proposal" should read "hypothesis", "idea", or "view"; etc.
Referee #2 (Remarks to the Author):
Monnier et al have used a domain deletion approach to assess whether GABA-B receptor monomers crosstalk through interactions of their 7TM domains. A novel surface labeling-FRET approach was used to demonstrate receptor complex assembly at the cell surface, coupled with downstream signaling assays to assess receptor function and ligand binding studies to assess receptor affinity states. The authors conclude that GB1 7TM directly allosterically activates the GB2 7TM domain.
Major concerns:
Overall, the manuscript lacks any statement of statistical rigor, including indications of numbers of experimental replicates, of composite versus representative assays in graphs, or of statistically significant differences. This make assessment of sweeping statements about differences impossible to assess. For example, it is stated of Figure 2 that the "isoproterenol effect was largely dimished upon GABA application", which is a fair assessment of Fig 2C but a vast overinterpretation of Fig  2D . In Fig 2D, there is almost no inhibition of Iso-stimulated cAMP production, measured using a BRET biosensor for intracellular cAMP. Additional examples below.
The logic of the manuscript is that GB1 to GB2 allostery is shown that does not require the GB2 VFT domain, and this also does not require the GB1 VFT domain; therefore it must be GB1 7TM to GB2 7TM allostery. This flow of logic is not supported by the data shown. Allostery of GB1 to the GB2 7TM is concluded from Figures 2D, 3D and 4D. Allostery of the GB1 7TM to the GB2 7TM is inferred from Figure 5 . Each experiment has complications that weaken the proposed interpretation. That a distinct receptor (mGlu1) cannot be made to function allosterically with GB1 ( Figure 6 ) is immaterial to the question at hand.
From Figure 2D , it is not clear whether GABA significantly reduces Iso-stimulated cAMP production, casting doubt on the real functionality of the receptor lacking the GB2 VFT. This needs to be quantified over a number of replicate experiments (perhaps cAMP signal over 5 min) to determine significance. Figure 3C shows that CGP35348 is >100 fold less effective than GABA on the wildtype receptor. Since GABA itself is 100-fold less effective at the receptor lacking GB2 VFT, it is no surprise that CGP appears inactive at this mutant receptor at the highest dose tested, making this experiment inconclusive regarding coupling per se. Figure 4 shows that CGP7930 and CGP39783, two allosteric modulators of GB2, differentially affect wildtype receptor and receptor lacking GB2 VFT. Because these compounds (plus low doses of GABA) induce elevated calcium flux in cells expressing the receptor lacking GB2 VFT, the authors conclude that these compounds are agonists and that "GB2 VFT is needed to maintain the wild-type receptor in its inactive state". This is clearly not the case, as clearly shown in Figure 3B , where the GB2 VFT has a lower basal PI hydrolysis activity than the wildtype receptor, not increased activity. Further, if CGP7930 and CGP39783 are purported to be agonists, they must be tested without any GABA present, since they may be allosterically affecting receptor function only in the presence of low GABA. It seems likely that these compounds have complex effects on GABA-B receptor function, and perhaps the increased accessibility or reduced constraints of the GB2 VFT mutant allows the compounds to have altered allosteric effectiveness for the same amount of binding. These compounds do appear to increase GABA affinity at the wildtype receptor ( Figure  4C ), but again, the small apparent effect on the GB2-VFT mutant receptor in Figure 4D is of unclear statistical significance.
Together, these three experiments do not convincingly demonstrate that the GB1-GB2 delVFT receptor has allosteric regulation independent of the GB2 VFT domain.
Regarding allostery of GB1 7TM to GB2 7TM, Figure 5 is unconvincing. The authors claim that each receptor complex is indeed a complex because HA-GB1 is at the cell surface (Supp Figure 5) . However, the GB1/GB2 chimera has the GB2 tail and should traffick to the cell surface unfettered, and there is no assessment to show that GB1 VFT or GB2 VFT is actually associated with the GB1/GB2 chimera. Similarly, since the GB1 VFT fusions with a GPI anchor or a single transmembrane domain lack the GB1 retention signal, they should traffick to the cell surface; but are they physically associated with the GB2 subunit? If not, then their lack of signaling together with GB2 is uninformative. The association of each receptor complex must be demonstrated for this experiment to have a meaningful interpretation.
Minor concerns:
The authors are clearly trying very hard to be very clear about what mutants are used in each experiment, and the receptor subunit icons with each panel are wonderful. Still, the figures/legends can be too vague and under-described. For instance, the meaning of the open versus closed bars in Figure 1B is not obvious. In Figures 1C and 6B , are these graphs the result of transfections at various levels?
The manuscript has numerous grammatical errors that should be corrected, for example: abstract, "Seven transmembrane domains" should be "domain"; "receptor deleted of" should be "receptor lacking"; "the actual model" should be "the current model". Introduction page 4, "we even developed" should be "we developed"; "allowed us to examined" should be "examine". Results page 5, "Interestingly, meanwhile" should be "Interestingly, while"; page 6 "to a lesser extend" should be "extent".
Additional correspondence 22 May 2009
Many thanks for taking a final decision as based on the comments of the first two reviewers.
First of all we were really pleased to see that the referees did not make any comment on the new approach that we described to analyze the interaction of two cell surface proteins, and based on a combination of snap-tag and ACP-tag labeling with new TR-FRET subtrates.
When considering the comments of the second reviewer, we realized that these are mostly minor remarks that can be very easily corrected (statistical validation of our data; and adding additional FRET experiments to demonstrate the association of the various constructs tested). Indeed, we already have most of the requested data.
The comments of the first reviewer are more serious since he/she is not convinced of a direct transactivation between the two 7TM domains of the GABAB receptor. We think, this reviewer under-estimated the meaning of the non-functionality of constructs like GB1-TM and GB1-GPI co-expressed with the full length GB2. Indeed, if the reviewer's proposal is correct, that GB1-VFT can directly activate the 7TM domain of GB2, such subunit combinations should be functional (note that, as requested by the second reviewer, we are able to provide direct FRET demonstration, as based on the new technology described in our paper, of the correct assembly of the subunits).
We also have additional data that we are ready to include in this manuscript, in which the addition of a large steric hindrance on top of the GB2-7TM, expected to prevent GB1-VFT from directly activating the 7TM region of GB2, does not prevent GABA from activating the GB1-∆VGB2 receptor combination, bringing a new argument in favor of the direct transactivation between the 7TMs.
One argument used by the first referee to reject our proposal is that swapping the VFTs between the subunits lead to a receptor with very similar properties as the wild-type. However, the referee did not considered that in such a receptor combination it is quite likely that the domains are positioned like in the wild-type receptor.
Then, if you are convinced that our ms still brings important information to the field (a new technology, plus evidence for a direct transactivation between 2 7TMs), we would appreciate if you could re-consider your decision, especially if you can get the comments from the third referee and if these are more positive.
In any case, we will certainly find very useful to receive the comments of the third referee as soon as you receive them.
Thank you for your message asking us to reconsider our decision on your manuscript and to forward you the third report. In fact, we have just received the third report (see below). As you will see also referee 3 feels that -while he/she considers the study as potentially interesting -the evidence presented is not strong enough to fully and convincingly justify the conclusions drawn. Taking together all three reports it thus becomes clear that while the referees consider the study as potentially important and significant they are not convinced that the evidence presented is strong and definitive enough to rule out possible alternative explanations for your findings which in their view would be required to support publication of the study here. As I had explained to you in my initial decision letter in a situation where it cannot be predicted whether the concerns raised and the controls required can be addressed in a manner that the main conclusions can be maintained we cannot consider and thus commit to a revision. Having said that I would like to point to the possibility to submit a new version as a new submission at a later stage if you feel confident that you can make a considerably more convincing case for your conclusions. However, we would need to treat such a new version as a new submission rather than as a revision and we would need to evaluate the paper again at the editorial level and to subject it to another round of in-depth peerreview using the same referees again if available at the time of resubmission. Otherwise new referees may need to be involved. Furthermore, the novelty of your findings will need to be assessed again at the time of resubmission. At this point, however, I need to point out that there cannot be any commitment from our side.
I feel that this procedure will address the matter in a fair and efficient manner.
Yours sincerely,
Editor
The EMBO Journal Referee #3 (Remarks to the Author):
The manuscript by Monnier et al describes a transactivation process between the GABABR1 and GABABR2 that does not appear to involve the GABA-binding, venus fly trap domain of GABABR2. The interaction appears to be mediated through direct interaction between the transmembrane domains only. The observation of such an interaction would be one of the first demonstrations of direct, interprotein transactivation within the membrane domains. This observation would have tremendous implications to the burgeoning field of receptor hetero-and homo-oligomerization field and provide a rationale for the complicated pharmacology of some receptor systems.
Provided that the authors provide either the data or a compelling argument for the major comment below the nature and impact of the findings will be a considerable interest to the GPCR field.
Major Comment:
The authors provide several key pieces of data to suggest that the TM regions of the BR1 can allosterically modify the behavior of G the protein-coupling capacity of BR2. From the data reported in the manuscript, supplement and previous reports by the same group, there seems to be a couple of key experiments missing. The main argument that the authors make implies that the transactivation occurs solely through the TM domain, in this system. The data do not exclude the possibility that the transactivation may occur from the VFT domain directly regulating the activity of the TM regions of GB2. Many of the experiments and results describe are close but do not directly assess this possibility. For example, figure 5 illustrates a collection of combinations of truncations and fusion proteins of the GB1 and GB2 receprtors. It is curious why the authors chose not report the testing of the TM-linked (or GPI-linked) VFT domain of GB1 with the TM-only containing domain of GB2.
In the manuscript the authors argue that the VFT of GB1 does not interact with the TM domain of GB2, based on receptor chimera data, ie. VFT(GB1)-TM(GB2) fusion protein. This is not the same experiment since the constraints induced by the chimera may not act in a productive manner. The authors did test the lipid-anchored VFT of GB1 with full length GB2, however in light of the effect of VFT2 on the basal activity of GB2, it is not likely that direct allosteric regulation of 7TM-GB2 may be optimal.
Minor Comment:
The authors claim that CGP35348 failed to activate the GB1-7TM-GB2. Seeing that GABA was 100-fold less potent than with wt-GB1-GB2 then CGP35348 should also be 100-fold less potent. Although it may not be possible to test higher concentrations (due to solubility etc) it should be stated that "CGP35348 failed to activate in this concentration range". Answer to the referee #1:
Conceptual issues: 1. (Figs. 2,3,4 in Galvez et al., 2001 ).
In their nice cartoons in the figures the authors illustrate possible flow of information within GABA-B receptor consisting of four structural components: GB1-VFT, GB1-7TM, GB2-VFT, and GB2-7TM. Unfortunately, they a priori excluded two possible directions: from GB1-VFT to GB2-7TM and from GB2-VFT to GB1-7TM. While the latter is likely irrelevant in GABA-B receptor (although not in homodimeric class C GPCRs, such as mGluRs), the GB1-VFT to GB2-7TM can account for the results presented here just as convincingly as the explanation favored by the authors, i.e., that activation is transmitted from GB1-VFT to GB1-7TM, and then to GB2-7TM. Similarly, direct "backtalk" from GB2-7TM to GB1-VFT can account for the binding data at least as well as the mechanism involving GB1-7TM that the authors favor. The authors argue that a single subunit combining GB1-VFT and GB2-7TM is inactive, but the relative orientation of these two parts in a single subunit and in GB1-delta-VFT-GB2 is quite different. Importantly, the same GB1-VFT + GB2-7TM subunit in the context of a dimer where the other subunit consists of two "useless" parts, GB2-VFT that does not bind GABA plus GB1-7TM that does not couple to G proteins, is quite active
As pointed out by the reviewer, to prove that transactivation occurs between 7TMs in the GB1 + delta-VFT-GB2 heterodimer during receptor activation, it is necessary to show that direct communication between GB1 VFT and GB2 7TM is very unlikely. In this revised version, we have now added three new sets of data that further support our original conclusion on the transactivation between the 7TMs of GB1 and GB2, particularly the third approach.
1-We first assumed that to allow a direct allosteric coupling between GB1 VFT and GB2 7TM, GB1 VFT had to contact GB2 7TM over a reasonable area. We thus hypothesized that by introducing a steric hindrance in the extracellular surface of GB2 7TM we could prevent such coupling. To this aim, we fused either at the N-terminus or in the second extracellular loop of GB2, either a SNAP-tag or an ACP-tag (182 and 77 residues, respectively) ( Figure 6B ). The observation that all these subunits could still be activated by GB1 further limits the possibility that the VFT domain of GB1 acts directly on the 7TM domain of GB2. 2-In a second set of experiments we examined whether a direct activation between GB1
VFT and GB2 7TM could be obtained by co-expressing these two domains individually. The GB1 VFT was maintained at the cell surface through a single TM (TM7), and its physical association with GB2 7TM was made stable thanks to an intracellular coiled coil interaction between the C-terminal tails of both constructs. We then showed that GB1 VFT on its own cannot transactivate GB2 7TM, despite their physical association and cell surface expression, as demonstrated by cell surface FRET (Figure 7 and Supp Figure 7B ). This experiment strongly suggests that GB1 7TM is required for the transactivation of GB2 7TM. However, it could still be argued that, in such an experiment, GB1 VFT is not correctly positioned relative to GB2 7TM, thus preventing allosteric coupling. 3-We then aimed at demonstrating that a specific conformation of GB1 7TM is needed for transactivation to occur. Among a series of double cysteine mutants of GB1 7TM, we identified one in which the conformational space is likely to be limited through the insertion of two facing cysteine residues and that could no longer transactivate the isolated 7TM of delta-VFT-GB2, while it could still form a functional GABA B heterodimer with full length GB2 ( Figure 7 ). This last set of data demonstrates the pivotal role of GB1 7TM in the transactivation of the isolated 7TM of delta-VFT-GB2. As expected activation could still be obtained in the full length heterodimer, because of the alternative pathway that involves the VFT relative movement.
As mentioned by the reviewer, co-expression of two chimeric subunits GB1/2 (composed of GB1 VFT linked to GB2 7TM) and GB2/1 (GB2 VFT linked to GB1 7TM) provided a functional GABA B receptor (Galvez et al., 2001 ) with similar properties to those of the wild type receptor. Since the GB1/2 chimera expressed alone or co-expressed with delta-VFT-GB1 (data not shown since removed in the new manuscript) or delta-VFT-GB2 ( Figure 6A ) is not functional, the easiest explanation for the Galvez et al. data is that an exchange (a domain swapping) between the two VFTs could occur when GB1/2 and GB2/1 are co-expressed, such that the VFT of GB1 will be associated with GB1 7TM and the VFT of GB2 with GB2 7TM, similarly to what is expected to occur in the wild type receptor. This domain swapping hypothesis is also compatible with the observation that the length of the linker between the VFT and 7TM in both GB1 and GB2 can be increased without much consequences on receptor activation (Margeta-Mitrovic et al. (2001) PNAS 98, 14643-14648) . (Galvez et al., 2001) , in which both subunits have 7TM domain from GB2, shows that both mutant receptors are functional. As far as one can compare different assays used here and in (Galvez et al., 2001) 
The comparison of WT GABA-B receptor with GB1-delta-VFT-GB2 characterized here and GB1/2-GB2 described in

, GB1-delta-VFT-GB2 is more impaired relative to WT than the mutant with two GB2 7TMs. According to the authors, in the latter construct 7TM-7TM transactivation should not be happening, which leaves cross-subunit GB1-VFT to GB2-7TM transmission as the only viable route.
First, GB1+delta-VFT-GB2 and GB1/2+GB2 receptor complexes are activated by GABA with similar potency (about 100 times lower potency than for the wild type receptor). However, the affinity of GB1+delta-VFT-GB2 for the GABA is lower than the wild type (Fig. 3A) , whereas that of GB1/2+GB2 is not affected (Galvez et al., 2001 ). As we mentioned in the ms, this difference is due to the absence of GB2 VFT in GB1+delta-VFT-GB2, indicating that one role of GB2 VFT is to increase agonist affinity in GB1 as previously reported (Liu et al. (2004) JBC 279, 15824-15830) . Secondly, GB1-VFT to GB2-7TM transmission is unlikely to explain the activity of the combinaison GB1/2+GB2, as discussed above. In the GB1/2+GB2 receptor heterodimer, activation may occur mainly through the two VFTs (see Discussion, pathway 1). We know that this transactivation can occur in the absence of GB1 7TM since delta-7TM-GB1 (called GB1-TM7 in the manuscript) co-expressed with GB2 can be activated by GABA (see new data in Figure 7A ).
3.
The The reviewer is right, the relative movement between the two VFTs of the GABA B receptor is critical for the activation of the wild type heterodimer since prevention of this movement using a glycan wedge suppressed receptor activation (Rondard et al., EMBO J 2008) . Moreover, the deletion of GB1 7TM (replacement of 7TM by a unique TM: GB1-TM7 subunit) produced a functional receptor with a 100 times lower potency (see Figure 7) . However, our present data revealed a second route for transactivation between the GABA B binding site and the G-protein coupling site that involves a direct transactivation between the 7TMs. By no way these two observations are incompatible. Instead, taken together our data reveal that the allosteric coupling between the GB1 and GB2 subunits occurs at several levels, along the two subunits, possibly to make this process more effective, and also to offer a number of possibilities to modulate receptor activation. Our previous observation that preventing the relative VFT movement fully suppresses receptor activation in the full length receptor, indicates that such a process is needed, not only for the first allosteric route, but also for the second one. This indicates that, in the presence of the GB2 VFT, the movement of GB1 VFT relative to the GB1 7TM involved in the second route is impaired.
Presentation issues: 4.
In the intro, the authors state "It is accepted that these 7 transmembrane domains (7TM) proteins can associate into dimers or oligomers (Ferre et al., 2009; Terrillon and Bouvier, 2004) , then possibly offering a new level of complexity and the development of more specific drugs", implying that this is a generally accepted paradigm. In fact, with the exception of class C receptors (to which GABA-B belongs), the issue of GPCR dimerization and its possible functional significance is highly controversial. The authors should clearly state that they are discussing class C receptors and avoid lumping all GPCRs together.
As suggested, we largely modified this sentence to be less affirmative on the existence of dimer and oligomers. However, we recently revealed the existence of a class A GPCR homodimer (the oxytocin receptor) in native tissues (Albizu et al. (2010) Nat Chem Biol 6, 587-594) . This reference was included in the new sentence.
5.
The text needs some editing. In the abstract, "receptor deleted of the GABAB2 extracellular domain" should read "receptor where the GABAB2 extracellular domain was deleted"; p.6, "largely diminished" should read "significantly diminished"; in many places "proposal" should read "hypothesis", "idea", or "view"; etc. The manuscript was carefully read and corrected by a scientific editor fluent in English. The changes proposed by the reviewer have been made. Figure 2 that the "isoproterenol effect was largely dimished upon GABA application", which is a fair assessment of Fig 2C but a vast overinterpretation of Fig  2D. In Fig 2D, there is almost no inhibition of Iso-stimulated cAMP production, measured using a BRET biosensor for intracellular cAMP. Additional examples below.
Answer to the referee #2:
Monnier et al have used a domain deletion approach to assess whether GABA-B receptor monomers crosstalk through interactions of their 7TM domains. A novel surface labeling-FRET approach was used to demonstrate receptor complex assembly at the cell surface, coupled with downstream signaling assays to assess receptor function and ligand binding studies to assess receptor affinity states. The authors conclude that GB1 7TM directly allosterically activates the GB2 7TM domain.
Major concerns: Overall, the manuscript lacks any statement of statistical rigor, including indications of numbers of experimental replicates, of composite versus representative assays in graphs, or of statistically significant differences. This make assessment of sweeping statements about differences impossible to assess. For example, it is stated of
The reviewer is right to point out the necessity of a rigorous statistical analysis. We are sorry we omitted to include this in our first version of the ms. Statistical analysis is now included in the figure legends. For Figure 2D , our statistical analysis shows that GABA significantly reduced isoproterenol effect. Accordingly, the corresponding sentence in the Results section has been changed: " The effect of isoproterenol was significantly diminished following co-incubation with GABA in cells expressing the wild type receptor heterodimer (GB1+GB2) (Fig. 2C ) and, to a lesser extent, also in cells expressing the GB1+∆VGB2 heterodimer (Fig. 2D) ".
The logic of the manuscript is that GB1 to GB2 allostery is shown that does not require the GB2 VFT domain, and this also does not require the GB1 VFT domain; therefore it must be GB1 7TM to GB2 7TM allostery. This flow of logic is not supported by the data shown. Allostery of GB1 to the GB2 7TM is concluded from Figures 2D, 3D and 4D. Allostery of the GB1 7TM to the GB2 7TM is inferred from Figure 5. Each experiment has complications that weaken the proposed interpretation. That a distinct receptor (mGlu1) cannot be made to function allosterically with GB1 (Figure 6) is immaterial to the question at hand.
As pointed above, we hope that the new data included will convince the referee that a direct cross talk can occur between GB1 7TM and GB2 7TM (see our answer to the first point of Referee 1). Again, and as stated above, we do not conclude that this is the only route for the signal coming from agonist binding to GB1 VFT to reach the G-protein coupling site in GB2 7TM. The experiment using the mGlu1 7TM was performed to examine the specificity of the transactivation mechanism. This experiment suggests that the coupling between the GB1 and GB2 7TM domains is selective (see new Figure 5 ). Then in the next two figures (Figures 6 and 7) , we present three new sets of data that support the most plausible explanation for the activity of the GB1+∆VGB2 heterodimer: direct transactivation between the 7TM of GB1 and GB2 (see Response to the first point of Referee 1 for details).
From Figure 2D, it is not clear whether GABA significantly reduces Iso-stimulated cAMP production, casting doubt on the real functionality of the receptor lacking the GB2 VFT. This needs to be quantified over a number of replicate experiments (perhaps cAMP signal over 5 min) to determine significance.
This experiment was performed more than three times. In each experiment, the statistical analysis shows that GABA significantly reduced isoproterenol effect in cells expressing the GB1 and ∆VGB2 combination. Figure 2D presents the data of one of these experiments. The statistical analysis is described in the Materials and Methods section.
Figure 3C shows that CGP35348 is >100 fold less effective than GABA on the wildtype receptor. Since GABA itself is 100-fold less effective at the receptor lacking GB2 VFT, it is no surprise that CGP appears inactive at this mutant receptor at the highest dose tested, making this experiment inconclusive regarding coupling per se.
The reviewer is right. Since CGP35348 is about 100 fold less effective than GABA on the wild type receptor and the GB1+∆VGB2 heterodimer activates G-protein with about 100 times lower potency, it is true that CGP35348 was not expected to generate a calcium response with the GB1+∆VGB2 combination at the concentration used. Accordingly, we do not draw any conclusion from this data in the revised manuscript. Figure 3B , where the GB2 VFT has a lower basal PI hydrolysis activity than the wildtype receptor, not increased activity.
Figure 4 shows that CGP7930 and CGP39783, two allosteric modulators of GB2, differentially affect wildtype receptor and receptor lacking GB2 VFT. Because these compounds (plus low doses of GABA) induce elevated calcium flux in cells expressing the receptor lacking GB2 VFT, the authors conclude that these compounds are agonists and that "GB2 VFT is needed to maintain the wild-type receptor in its inactive state". This is clearly not the case, as clearly shown in
The reviewer is right, our sentence was inappropriate. Indeed, what we meant is that GB2 VFT is important to prevent GABA B PAMs to efficiently activate the wild type heterodimer. Indeed, the deletion of GB2 VFT revealed a much more effective agonist action of both PAMs: the agonist activity of GS39783 can now be measured and that of CGP7930 is greatly increased. We thus modified this sentence in the new version of our manuscript.
Further, if CGP7930 and CGP39783 are purported to be agonists, they must be tested without any GABA present, since they may be allosterically affecting receptor function only in the presence of low GABA. It seems likely that these compounds have complex effects on GABA-B receptor function, and perhaps the increased accessibility or reduced constraints of the GB2 VFT mutant allows the compounds to have altered allosteric effectiveness for the same amount of binding.
In the original version of the manuscript, CGP7930 and GS39783 were indeed tested in the absence of GABA, but it was not clear in Figure 4 . In the new version of Figure 4 , we clearly present the effect of the two positive allosteric modulators in the absence of GABA. In the GABA B receptor lacking GB2 VFT, the agonist efficacy of the two compounds is largely increased. Figure 4C ), but again, the small apparent effect on the GB2-VFT mutant receptor in Figure 4D is of unclear statistical significance.
These compounds do appear to increase GABA affinity at the wildtype receptor (
This experiment was performed three times for the GB1+∆VGB2 combination. In each experiment, statistical analysis showed that the apparent affinity for GABA was significantly increased in the presence of CGP7930 or GS39783. Figure 4D presents the data obtained for one of these experiments.
Together, these three experiments do not convincingly demonstrate that the GB1-GB2 delVFT receptor has allosteric regulation independent of the GB2 VFT domain.
As explained above (see our answer to the first point of the first referee), three additional sets of data using three different experimental approaches are consistent with a transactivation mechanism between the GB1 and GB2 7TM domains for the GABA B receptor lacking GB2 VFT. These new data are presented in two new figures, Figure 6 and 7. Figure 5) . However, the GB1/GB2 chimera has the GB2 tail and should traffick to the cell surface unfettered, and there is no assessment to show that GB1 VFT or GB2 VFT is actually associated with the GB1/GB2 chimera.
Regarding allostery of GB1 7TM to GB2 7TM, Figure 5 is unconvincing. The authors claim that each receptor complex is indeed a complex because HA-GB1 is at the cell surface (Supp
In the new version of the manuscript, Figure 5 is now Figure 6A . As suggested by the reviewer, we did prove that the GB1/GB2 chimera (GB1/2) can associate directly with GB2 7TM by performing time-resolved FRET experiments on the cell surface receptors using non-cell permeable snap-tag fluorescent substrates (Supp Figure 7A) . However, in the new Figure 6 , we removed the data on the co-expression of GB1/2 and delta-VFT-GB1 since we were not able to measure enough FRET signal between these two subunits.
Similarly, since the GB1 VFT fusions with a GPI anchor or a single transmembrane domain lack the GB1 retention signal, they should traffic to the cell surface; but are they physically associated with the GB2 subunit? If not, then their lack of signaling together with GB2 is uninformative. The association of each receptor complex must be demonstrated for this experiment to have a meaningful interpretation.
We replaced the results obtained with the GB1 VFT anchored to the plasma membrane by either a GPI or TM1 by those obtained with the GB1-TM7 subunit in which GB1 VFT is associated with the 7 th TM of GB1 plus the C-terminal tail of GB1 that contains the endoplasmic retention signal (see new Figure 7 ). Indeed, only this subunit could form stable dimers with the GB2 subunits at the cell surface, thanks to the coiled-coil interaction of their C-terminal tails, as validated by cell surface TR-FRET (see Supp Figure 7B ). The absence of activity of GB1-TM7 + deltaVFT-GB2, while GB1-TM7 + wild type GB2 is functional, shows that the GB1 VFT cannot activate directly an isolated GB2 7TM ( Figure 7A ).
Minor concerns:
The Figure 1B is not obvious. In Figures 1C and 6B , are these graphs the result of transfections at various levels?
The figures and figure legends, in particular Fig. 1B, 1C and 6B (now Fig. 1B, 1C and 5B) have been improved.
The manuscript has been carefully read and corrected by a scientific editor fluent in English, and the corrections proposed by the reviewer have been made.
Answer to the referee #3:
The manuscript by Monnier et al describes a transactivation process between the GABABR1 and GABABR2 that does not appear to involve the GABA-binding, venus fly trap domain of GABABR2. The interaction appears to be mediated through direct interaction between the transmembrane domains only. The observation of such an interaction would be one of the first demonstrations of direct, interprotein transactivation within the membrane domains. This observation would have tremendous implications to the burgeoning field of receptor hetero-and homo-oligomerization field and provide a rationale for the complicated pharmacology of some receptor systems.
Provided that the authors provide either the data or a compelling argument for the major comment below the nature and impact of the findings will be a considerable interest to the GPCR field. As suggested by all three reviewers, we present three new sets of data that, together, strongly support the mechanism of transactivation between GB1 and GB2 7TMs (see details in the response to referee #1). In one of these sets of experiments, we performed the key experiment proposed by referee #3. We co-expressed the VFT domain of GB1 linked to the seventh TM ( SNAP GB1-TM7) with the TM-only containing domain of GB2 (ΔVGB2; see new Figure 7 ). We show that SNAP GB1-TM7 can interact directly with GB2-7TM at the surface of cells in time-resolved FRET experiments (see Supp Figure 7B ). However this complex cannot activate G-protein ( Figure 7A ). We prove that the absence of activity is not due to a problem with the SNAP GB1-TM7 construct since it can provide a functional receptor when co-expressed with full length, wild-type GB2 ( Figure 7A ). These results show that GB1 VFT cannot activate GB2 7TM at least when these two isolated domains are coexpressed.
Minor Comment:
The authors claim that CGP35348 failed to activate the GB1-7TM-GB2. Seeing that GABA was 100-fold less potent than with wt-GB1-GB2 then CGP35348 should also be 100-fold less potent. Although it may not be possible to test higher concentrations (due to solubility etc) it should be stated that "CGP35348 failed to activate in this concentration range".
The referee is right (see above, response to referee #2). In the revised manuscript, we modified the sentence as proposed by the reviewer.
Should describe the use of "heteromer" vs heterodimer/heterotetramer/etc.
For simplicity, we hypothesized that all the receptor complexes were dimers. We thus replaced « heteromer » by « heterodimer ».
What is Galphaqi9 ?
Galphaqi9 is a Galphaq in which the last nine C-terminal residues are replaced by those of Galphai2). This information was included in the Results section of the manuscript. Supplemental Fig 2 ? .
What is the [GABA] used in
We used concentrations near the EC 80 of GABA for the wild type and truncated GABA B receptor, 300 nanoM and 100 microM GABA, respectively. These values have been added into the Supplemental Fig. 2 Thank you for submitting a new version of your manuscript (originally EMBOJ-2009-70998) for consideration by The EMBO Journal. Our original referees have now seen it again, and you will be pleased to learn that, in general, the referees are now positive about publication of your paper here.
Still, the referees all put forward a number of issues (see below) that should still be addressed before we can ultimately accept your manuscript. In particular, referee 2 raises concerns regarding your interpretation of the findings and I would like to ask you to address or respond to his/her concerns. Furthermore, and as also mentioned by the referees, it will be highly advisable for you to take another careful look through the text and to correct and improve the spelling and grammar throughout. I would therefore urge you to have a native English speaker read the final draft before returning it to our office.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Peer Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
Thank you again for the opportunity to consider your work for publication. I look forward to your re-revised manuscript.
Editor
The EMBO Journal
The manuscript is much improved by the addition of new data and by clarifications to the text.
One minor issue is in the argument that GABA-B receptor activation utilizes both GB1-TM and GB1-VFT to activate GB2. Data in favor of this is shown in Figure 7A for calcium signaling from two types of partially-hobbled receptors that can only use one or the other type of coupling, but there is no comparison to the wildtype receptor. Could the authors compare these results to calcium signaling by wildtype receptor (perhaps just by citing an earlier work)?
rather than the extracellular, GABA-binding, venus fly trap domain of GABABR2. The observation of such an interaction would be one of the first demonstrations of direct, inter-protein transactivation within the membrane domains. These observations have tremendous implications to the burgeoning field of receptor hetero-and homo-oligomerization field and may provide a explanation for the complicated pharmacology of some receptor systems.
The revised manuscript represents a substantial improvement over the original manuscript as several key experiments were included. There are some minor comments (below) that the authors may consider addressing. In addition, there are numerous spelling and grammatical errors scattered throughout the manuscript (below).
Minor comments:
P12: Is the function of the "empty" VFT1 to stabilize the inactive conformation of TM2 ? This may be overcome by either the addition of GABA binding to VFT1 or the allosteric modulator (CGP7930) binding to TM7(2).
General: "G protein" is not hyphenated.
P7: "5 folds" and "100 folds" should be "5-fold" and 100-fold", respectively We wish to thank the referee for his very positive comments about the quality of our data, especially when he states that they represent "the best evidence for this phenomenon (i.e; transactivation between TMs) yet". The referee is right in saying that our finding that the GB1DCRC-GB2 combination can be activated by GABA could indicate that trans-activation between the 7TMs does not occur in the full length receptor. We should have discussed this possible interpretation in our original manuscript. This is now the case in the new revised version.
Because the DCRC mutation prevents activation of the truncated GB2 7TM, then the comparison of the activity of the wild-type GB1-GB2 receptor, with that carrying this double mutation in the GB1 7TM can theoretically give some hints on the role of the 7TM transactivation process in the activity of the wild-type receptor. Surprisingly, the receptor carrying the DCRC mutation displays a higher G protein coupling efficacy than the wild-type. Per se this observation already suggests that something special is occuring at the level of the GB1 7TM DCRC mutant that appears different between the GB1-∆VGB2 and the wild-type receptors.
Although we cannot exclude the possibility that trans-activation between the 7TMs does not occur in the wild type receptor, we find this possibility very unlikely, for several reasons.
First, it would be quite surprising if such a complex allosteric coupling between 7TMs occurred only in the GB1-∆VGB2 mutant. Indeed, such allosteric coupling is likely to require a specific and precise interaction between the two 7TM domains. This is well illustrated by the finding that transactivation does not occur between the 7TMs of GB1 and of mGlu or between two GB2 7TMs (as illustrated by the very low coupling efficacy of the GB1/2-∆VGB2 combination). If such a process resisted to evolution, it is likely because it is important for the proper functioning of the receptor. Otherwise, one would have to explain me how such a precise process can resist to evolution if not being useful.
Second, the finding that the GB1-DCRC+GB2 receptor displays higher G protein coupling efficacy than the wild type heterodimer does not automatically means that 7TM trans-activation does not occur in the wild type receptor. As clearly stated in our manuscript, the relative movement of the VFTs in the wild type receptor represents the critical step in the receptor activation. Then, the positioning of the two VFTs can lead to two allosteric pathways: a first one from the GB2 VFT to the GB2 7TM, and a second one from the GB1 VFT to the GB1 7TM and then to the GB2 7TM. This second pathway is the one we describe in the present manuscript using the GB1+∆VGB2 truncated heterodimer. Its lower efficacy and potency in comparison to the wild type receptor is due to the fact that in the absence of the VFT of GB2, the VFT of GB1 is far less efficient in activating the 7TM of GB1. As a consequence, any energetic barrier in the system (such as the DCRC mutation) blocks this allosteric pathway. This explains why the GB1-DCRC+∆VGB2 receptor heterodimer is inactive. In the wild type receptor, we can suppose that GB1 VFT can be more efficient in activating GB1 7TM due to the movement between the VFTs. Moreover, since GB2 VFT also might activate GB2 7TM, the active conformation of GB2 7TM will also participate in stabilizing GB1 7TM in its activating conformation (the reciprocity in the allosteric process). Altogether, these events can help overcoming the energy barrier that results from the DCRC mutations, thus allowing the receptor to reach the same active conformation as in the wild type receptor. The hindrance brought about by the DCRC mutations may even further stabilize the active -In section "Selective coupling GB1 and GB2 7TM", one sentence has been added at the end, according to the minor comment of referee 2.
Discussion: -The first four paragraphs was modified, and the fourth one was rewritten to discuss the major issue raised by referee 2. -Five additional references were added in the fifth paragraph.
Figures:
- Figure 7 was modified according to the minor comment of referee 1. Panel A was modified to include data on the wild type receptor. Panel B is new. Panel C is the former Panel B. -Figure 8 was added.
Supplementary material:
- Supplementary Figure 9 was deleted since data from this figure were now included in Figure 7 .
Our manuscript has been re-edited by a person whose native language is English.
3rd Editorial Decision 05 October 2010
Thank you for sending us your revised manuscript. Our original referee 2 has now seen it again, and you will be pleased to learn that the paper will now be publishable in The EMBO Journal.
Before this will happen, however, I was wondering whether you would like to consider addressing the minor issues suggested by referee 2 (see below). Please let us have a suitably amended manuscript text file as soon as possible via e-mail. We will then upload it into the manuscript submission system for you and I will formally accept the manuscript.
Thank you very much again for considering our journal for publication of your work.
Editor
------------------------------------------------REFEREE COMMENTS referee 2
The data presented were excellent before. In this revision of the manuscript the authors presented clearer interpretations and discussed their results with a lot less bias. There are a few editorial changes that can be easily made in proofs:
p.12 "GABAB receptor deleted of GB2 VFT" and p.13 "GABAB receptor truncated of its GB2 VFT" should read "GABAB receptor with GB2 VFT deleted" or "GABAB receptor lacking GB2 VFT"; p.16, "could be specific of this obligatory GPCR heterodimer" should read "could be specific for this obligatory GPCR heterodimer".
